Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Abbott Laboratories (ABT) had Normalized Income after Taxes of $928.00M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$12.59B |
|
$928.00M |
|
$5.33B |
|
$7.27B |
|
$10.90B |
|
$1.69B |
|
$-169.00M |
|
$1.52B |
|
$1.52B |
|
$928.00M |
|
$928.00M |
|
$928.00M |
|
|
Normalized Income after Taxes |
$928.00M |
$1.69B |
|
-- |
|
-- |
|
1.74B |
|
-- |
|
$0.53 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
$0.00M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Cash Flow Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|